India to resume Export of Covid Vaccine next month

The resumption of Vaccine Maitri in the fourth quarter starting October 2021.

62
Air Cargo Import Export
Picture: Pixabay

Last Updated on September 21, 2021 by The Health Master

In order to fulfill the commitment of India towards the Covax global pool, the Central government will resume export of surplus Covid vaccines under Vaccine Maitri next month.

Addressing a press conference, Union minister of health and family welfare Mansukh Mandaviya announced the resumption of Vaccine Maitri in the fourth quarter starting October 2021.

Vaccines

“India will be resuming export of Vaccines under Vaccine Maitri in order to fulfill the commitment of India towards Covax, in line with our motto Vasudhaiva Kutumbakam,” he said.

He informed that the surplus supply of vaccines will be used to fulfill our commitment towards the world for the collective fight against Covid-19. Covax is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO.

Highlighting the importance of indigenous research and production of Covid vaccines in India, he said that it is due to the relentless efforts and guidance of Prime Minister that India was simultaneously undertaking research and production of Covid vaccines in line with the global developments.

India’s vaccination drive has been a role model for the world and it is marching ahead with great speed. More than 4 times we have crossed one crore since the vaccination drive commenced on January 16.

Informing about the expected production in the coming months, he said that more than 30 crore doses will be produced in October and more than 100 crores in the coming quarter vaccines will be produced.

Covishield

Covaxin

Sputnik V

WHO emergency use authorisation to Covaxin delayed till October 5

USFDA approves Pfizer booster shots only for people over 65

Future of Medical Device Regulation: Consultation by UK MHRA

Advantage of Jharkhand Pharma policy

India and Pharmacy Education: Chapter: 7

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner